ASCO conference highlights cancer treatment challenges amid scientific advances

The American Society of Clinical Oncology (ASCO) annual conference, the premier global gathering for cancer specialists, is underway, highlighting both significant scientific progress and persistent challenges in the fight against the disease.

This year's conference convenes an estimated 45,000 attendees in a sprawling venue described as being the size of 35 football stadiums. The event serves as a critical platform for disseminating the latest research and addressing the ongoing hurdles in treating cancer, a disease responsible for 10 million deaths and twice that number of new diagnoses annually worldwide.

Dr. Eric Small, ASCO President for the 2025-2026 term, a urological oncologist specializing in prostate cancer, is championing "translational medicine" as a central theme. His vision extends beyond simply moving discoveries from the lab to the clinic; it encompasses overcoming linguistic, geographic, cultural, and economic barriers to ensure treatments are accessible globally. "We can have incredible scientific discoveries, but the truth is they cannot be applied in all countries. How do you do that? It's not easy. The drug is available, but how much does it cost?" Small stated in an exclusive interview.

Despite advancements like genetic and molecular testing that enable targeted therapies, significant obstacles remain. The high cost and sophisticated technology required for these tests limit their accessibility, posing a major challenge to equitable cancer care. This issue is a focal point of discussions among the thousands of international delegates at the conference, as they seek to translate scientific breakthroughs into tangible benefits for patients worldwide.

“

We can have incredible scientific discoveries, but the truth is they cannot be applied in all countries. How do you do that? It's not easy. The drug is available, but how much does it cost?